JPWO2021209495A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021209495A5
JPWO2021209495A5 JP2022562446A JP2022562446A JPWO2021209495A5 JP WO2021209495 A5 JPWO2021209495 A5 JP WO2021209495A5 JP 2022562446 A JP2022562446 A JP 2022562446A JP 2022562446 A JP2022562446 A JP 2022562446A JP WO2021209495 A5 JPWO2021209495 A5 JP WO2021209495A5
Authority
JP
Japan
Prior art keywords
seq
nos
antigen
amino acid
flt3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022562446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522630A5 (https=
JP2023522630A (ja
JP7679399B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/059646 external-priority patent/WO2021209495A1/en
Publication of JP2023522630A publication Critical patent/JP2023522630A/ja
Publication of JP2023522630A5 publication Critical patent/JP2023522630A5/ja
Publication of JPWO2021209495A5 publication Critical patent/JPWO2021209495A5/ja
Application granted granted Critical
Publication of JP7679399B2 publication Critical patent/JP7679399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022562446A 2020-04-14 2021-04-14 抗ｆｌｔ３抗体及び組成物 Active JP7679399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009578P 2020-04-14 2020-04-14
US63/009,578 2020-04-14
PCT/EP2021/059646 WO2021209495A1 (en) 2020-04-14 2021-04-14 Anti-flt3 antibodies and compositions

Publications (4)

Publication Number Publication Date
JP2023522630A JP2023522630A (ja) 2023-05-31
JP2023522630A5 JP2023522630A5 (https=) 2024-04-22
JPWO2021209495A5 true JPWO2021209495A5 (https=) 2024-04-22
JP7679399B2 JP7679399B2 (ja) 2025-05-19

Family

ID=75530015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562446A Active JP7679399B2 (ja) 2020-04-14 2021-04-14 抗ｆｌｔ３抗体及び組成物

Country Status (16)

Country Link
US (2) US12252539B2 (https=)
EP (1) EP4136114A1 (https=)
JP (1) JP7679399B2 (https=)
KR (1) KR20220167331A (https=)
CN (1) CN115715297A (https=)
AU (1) AU2021255884A1 (https=)
BR (1) BR112022020683A2 (https=)
CA (1) CA3180188A1 (https=)
CL (1) CL2022002833A1 (https=)
CO (1) CO2022014520A2 (https=)
IL (1) IL297269A (https=)
MX (1) MX2022012919A (https=)
PE (1) PE20230075A1 (https=)
PH (1) PH12022552710A1 (https=)
TW (1) TWI910146B (https=)
WO (1) WO2021209495A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI910146B (zh) * 2020-04-14 2026-01-01 法商施維雅藥廠 抗flt3抗體及組合物
WO2024108163A2 (en) * 2022-11-18 2024-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd135 polypeptides
EP4637816A1 (en) * 2022-12-22 2025-10-29 The Medical College of Wisconsin, Inc. Compositions that target cd138 and cd3 and methods of making and using the same
IL325858A (en) * 2023-07-12 2026-03-01 Phenomic Ai Mediators of T cell activation against CTHRC1 and methods of using them
CN118924724B (zh) * 2024-07-29 2025-11-04 湖南大学 一种用于治疗神经母细胞瘤的药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7832394A (en) 1993-09-08 1995-03-27 Imclone Systems Incorporated Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
MXPA03003632A (es) 2000-10-24 2003-09-10 Immunex Corp Metodo para tratamiento de tumores usando terapia de combinacion.
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
HRP20160422T1 (hr) * 2009-12-23 2016-05-20 Synimmune Gmbh Protutijela protiv flt3 postupci njihove upotrebe
CA2961950A1 (en) * 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
AU2017382883B2 (en) * 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
CN118772278A (zh) * 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
JP7317718B2 (ja) * 2017-06-02 2023-07-31 ファイザー・インク Ｆｌｔ３を標的にするキメラ抗原受容体
CN113056486B (zh) * 2018-09-11 2025-06-17 德国肿瘤研究中心 改善的抗flt3抗原结合蛋白
JP7642542B2 (ja) * 2018-12-18 2025-03-10 ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド Ｆｌｔ３アゴニスト抗体及びその使用
TWI910146B (zh) * 2020-04-14 2026-01-01 法商施維雅藥廠 抗flt3抗體及組合物

Similar Documents

Publication Publication Date Title
JP7010811B2 (ja) ヒトｃｄ３結合抗体
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN105189562B (zh) Il-15异源二聚体蛋白及其用途
Chen et al. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
MX2012011234A (es) Anticuerpos contra csf-1r.
JP7689200B2 (ja) 抗ｃｎｔｎ４特異的抗体及びその使用
US11021538B2 (en) Bispecific coupled antibody, preparation method and application thereof
CN111388664A (zh) 干细胞增强疗法
JP2020527158A (ja) 多重特異性抗体混合物の生成およびその使用方法
JP2020533965A5 (https=)
JPWO2021044005A5 (https=)
JP2021526013A (ja) 抗ヒトｌａｇ−３モノクローナル抗体とその応用
CN120897754A (zh) 嵌合抗原受体
JPWO2023288241A5 (https=)
JPWO2021209495A5 (https=)
CN113980133B (zh) 抗体及其在抗肿瘤中的应用
CN112703038B (zh) 靶向CD38和TGF-β的抗癌组合疗法
CN113956359B (zh) 一种抗体及其在抗肿瘤中的应用
ES3041722T3 (en) Antibodies targeting tumor associated macrophages and uses thereof
CN113853389B (zh) 与gpnmb和cd3特异性结合的双特异性抗体及其用途
JP7396992B2 (ja) 上皮成長因子受容体に対する親和性が増加した抗体およびそれに由来するフラグメント
JPWO2021171257A5 (https=)
JP7162011B2 (ja) 癌糖ペプチドに対するモノクローナルおよびヒト化抗体
CN106963950B (zh) 用于治疗肿瘤的联合用药物
TWI918324B (zh) 抗FGFR2b抗體-藥物綴合物及其應用